

WE WORK FOR HEALTH

MAJOR MILESTONE: U.S. Life Sciences Investments Top $500B+

Pharmaceutical companies are continuing to invest big in America, **pledging more than $582 billion** since 2025. The surge in American-based investment strengthens the future discovery and delivery of life-altering treatment for U.S. patients while benefiting a sector of the economy that America must continue to secure its position in as a world leader. The life science industry supports **more than 4.9 million jobs**, including **262K+ in Pennsylvania** as of 2022.

IN PENNSYLVANIA

Billions of dollars of investment

At least four new manufacturing facilities, including from **Johnson & Johnson** (next-generation cell therapy), **Roche** (gene therapy production), **GSK** (next-generation respiratory and cancer medicines, based in Upper Merion) and **Eli Lilly** (next-generation weight loss therapies, based in Fogelsville)

Congress: Protect America's Position As the World Leader in Life Sciences. Oppose Importing Foreign Healthcare Policies & MFN Drug Pricing

Continued sector investment requires a policy environment that encourages innovation and protects American jobs. Global competitors, including China, are closing the gap.

Drug pricing policies like Most Favored Nation threaten America's biotech revolution.

230+ fewer new medicines over 10 years

1.1 million lost jobs

Surrender competitive edge to **China**

Fail to lower patient costs or address the real drivers of rising healthcare costs

Stay up-to-date on the latest life sciences' investment announcements and state-specific industry impact at weworkforhealth.org/investinamerica and weworkforhealth.org/in-the-states.